Oil prices hold sharp losses with focus on secondary India tariffs
Investing.com - UBS has reiterated its Neutral rating on Myriad Genetics (NASDAQ:MYGN) with a price target of $6.00, according to a research note from analyst Lu Li. The stock currently trades at $5.71, having fallen nearly 80% over the past year. According to InvestingPro analysis, the stock appears fairly valued at current levels.
The firm’s decision comes as Myriad Genetics management recently disclosed an updated corporate strategy without providing full implementation details. According to UBS, management explained they wanted to provide internal clarity while still developing the specifics, allowing for controlled execution of the strategy. InvestingPro data shows the company has struggled with profitability, though analysts predict a return to profits this fiscal year.
Management emphasized a clear shift from the previous approach where all business segments were treated equally. The new strategy places greater focus on the Cancer Care Continuum ( CCC (WA:CCCP)) going forward.
UBS noted that Myriad Genetics executives believe the current level of R&D investment should be sufficient to maintain growth in both the Prenatal and GeneSight businesses at or above market rates.
The company’s strategic pivot is expected to take time to execute and reflect in its profit and loss statement, according to management commentary shared in the UBS research note.
In other recent news, Myriad Genetics reported its second-quarter 2025 earnings, exceeding analyst expectations. The company achieved an adjusted earnings per share (EPS) of $0.05, outperforming the forecasted -$0.01. Additionally, Myriad Genetics reported a revenue of $213 million, surpassing the projected $201.9 million. These results highlight the company’s strong financial performance in the quarter. In another development, Myriad Genetics announced the promotion of Ben Wheeler to Chief Financial Officer, effective August 16, 2025. Wheeler has been with the company for over 13 years, holding several leadership roles, including Vice President and Corporate Controller. This leadership change marks a significant internal transition for Myriad Genetics. These recent developments reflect ongoing changes and achievements within the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.